Antibody-IL2 Fusion Protein Delivery by Gene Transfer.
Abstract
The purpose of the work described is to assess the feasibility of a gene therapy approach to deliver a specific antibody cytokine fusion protein called CC49-1L2 to a tumor expressing antigen reactive with the antibody. While gene therapy approaches to the delivery of immune stimulating compounds such as cytokines have been widely explored, less has been done investigating other molecules in these contexts. We further were interested in assessing a specific type of gene therapy for this purpose called particle mediated gene transfer in which the DNA of interest is deposited directly into cells using gas propelled gold beads as a delivery vehicle. In our studies, we first showed that a commonly used retroviral derived vector was the most effective at driving expression of the fusion protein. We also attempted to establish an immunotherapy model in which antibody reactive tumors were en grafted into syngeneic immunocompetent murine hosts. Growth of these tumors was monitored following PMGT of the FP at the tumor site. Our initial attempts at exploiting this model were unable to document a statistically significant anti-tumor effect.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1997
- Accession Number
- ADA338766
Entities
People
- Charles M. Nicolet
Organizations
- University of Wisconsin–Madison